Aims We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on
recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial. Methods and …

A post hoc analysis of Systolic Heart failure treatment with the I f inhibitor ivabradine Trial
(SHIFT) explored the efficacy and safety of ivabradine in severe heart failure (HF) as …

Aims In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate
reduction with ivabradine reduces the composite incidence of cardiovascular death and HF …

Background We analysed the effect of ivabradine on outcomes in heart failure (HF) patients
on recommended background therapies with heart rates≥ 75 bpm and< 75 bpm in the …

Background: Increased heart rate (HR) is an independent risk factor for cardiovascular
outcomes in chronic heart failure (HF). Ivabradine, an I f inhibitor, improved outcomes in …

Aims To test whether the efficacy and safety of the selective heart rate‐reducing agent
ivabradine changes according to age in chronic heart failure (HF) patients. Methods and …

Aims During the post‐discharge phase following a heart failure hospitalization (HFH),
patients are at high risk of early readmission despite standard of care therapy. We examined …

Incidence of chronic heart failure (HF) increases with age and cardiovascular (CV) morbidity.
Co-morbidities increase hospitalization and mortality in HF, and non-CV co-morbidities may …

Objectives: This study used the SHIFT (Systolic Heart failure treatment with the I f inhibitor
ivabradine Trial) database to assess the impact of background beta-blocker dose on …

Objective Ivabradine, a specific heart rate lowering therapy, has been shown in a
randomised placebo-controlled study, Systolic HF Treatment with the If Inhibitor Ivabradine …